Cabozantinib + NIVOLUMAB for carcinoid tumor

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Jan 2022: Trial started, NCT05263050
  2. 2 Mar 2022: Trial registered, NCT05263050

The trials

NCT05263050: Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

State
Under way
Phase
Phase 2
People
111 planned
Started
21 Jan 2022
Primary completion
Dec 2026
Arms
Cabozantinib and nivolumab
Results
None posted
  1. 21 Jan 2022: Trial started
  2. 2 Mar 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.